Shingrix demand outpaces supply

CDC: Expect ordering limits and shipping delays through June

Having trouble stocking Shingrix? It’s not you, it’s the supply. CDC recently updated its current list of current vaccine shortage and delays to include a note about the vaccine, stating providers should expect ordering limits and intermittent shipping delays through the end of June, regardless of whether they order the vaccine directly from the manufacturer, GlaxoSmithKline (GSK) or through wholesalers and distributors. The page notes that GSK is working to make more doses available.

 Despite the supply glitches, the recommendations for who should receive Shingrix remain the same, said Mitchel C. Rothholz, RPh, MBA, chief strategy officer at APhA.

“No prioritization of patients is recommended at this time. You may continue to offer the Shingrix vaccine to new patients and to those needing to complete their vaccine series. Decisions should be made based upon your practice and patient needs,” Rothholz said.

CDC recommends that healthy adults age 50 and older get two doses of Shingrix, 2 to 6 months apart. According to CDC, if you can’t administer a patient’s second dose within that timeframe, the patient won’t need to restart the series. However, the caveat is that data regarding the safety of alternative dosing regimens is limited and the efficacy of alternative dosing regiments has not been evaluated. If your patient gets the second dose less than 4 weeks after the first, the second dose should be repeated. Regardless, two doses are necessary, whether your patient has a history of herpes zoster or been immunized with live zoster vaccine.